Thursday 16 October, 2025
Objectives: Malaria is a life-threatening disease caused by protozoa of the genus Plasmodium which are spread to people through the…
Read moreAbstracts
Comparing Multiple Virtual Population Generation Approaches using as a base, a QSP Model of Rheumatoid Arthritis.
Thursday 16 October, 2025
Introduction: Virtual cohort and Virtual Population (VPop) generation are important outputs in the QSP process that attempt to capture the statistics…
Read moreHow to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition
Thursday 16 October, 2025
Objectives Quantitative system pharmacology (QSP) models are widely used in drug discovery and development to understand the complex interactions between…
Read moreDerisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies
Thursday 16 October, 2025
Objectives: The main objective of this study was to develop and qualify a Physiologically-Based Pharmacokinetics (PBPK) model able to predict…
Read moreA pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is one of the deadliest infectious diseases worldwide. Bedaquiline (BDQ), a drug used as part of combination…
Read moreModel-informed once-daily dosing strategy for children, adolescents and adults for bedaquiline and delamanid
Thursday 16 October, 2025
Objectives: The introduction of novel anti-tuberculosis drugs e.g. bedaquiline (BDQ), delamanid (DLM), and pretomanid, has revolutionized the treatment of drug-resistant…
Read moreInter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
Thursday 16 October, 2025
Objectives: We designed a physiologically based pharmacokinetic (PBPK)model of the anticancer drug oxaliplatin, and developed a scaling methodology that shows…
Read moreEvidence-based evaluation for race difference of pirfenidone using population pharmacokinetics model
Thursday 16 October, 2025
Introduction: Idiopathic pulmonary fibrosis (IPF), with a significantly high mortality rate, is a chronic, progressive disease primarily in the elderly….
Read moreBridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models
Thursday 16 October, 2025
Objectives: Many clinical trials generate both longitudinal biomarkers and time-to-event data. We might be interested in their relationship, as in the…
Read moreModelling the pharmacodynamics of rituximab biosimilar in children with rheumatological conditions
Thursday 16 October, 2025
Introduction: Following the expiration of rituximab’s patents in 2013 and 2016, rituximab biosimilars have emerged in clinical use in recent…
Read more